Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DMAC 
DiaMedica Therapeutics Inc (DMAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: DMAC (4-star) is a STRONG-BUY. BUY since 67 days. Simulated Profits (46.96%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.33
1 Year Target Price $12.33
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 92.55% | Avg. Invested days 45 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 349.42M USD | Price to earnings Ratio - | 1Y Target Price 12.33 |
Price to earnings Ratio - | 1Y Target Price 12.33 | ||
Volume (30-day avg) 4 | Beta 1.4 | 52 Weeks Range 3.19 - 7.49 | Updated Date 10/23/2025 |
52 Weeks Range 3.19 - 7.49 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -44.54% | Return on Equity (TTM) -73.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 332076391 | Price to Sales(TTM) - |
Enterprise Value 332076391 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.96 | Shares Outstanding 51688913 | Shares Floating 27067416 |
Shares Outstanding 51688913 | Shares Floating 27067416 | ||
Percent Insiders 26.47 | Percent Institutions 40.68 |
Upturn AI SWOT
DiaMedica Therapeutics Inc
Company Overview
History and Background
DiaMedica Therapeutics Inc. was founded in 2010 and focuses on developing novel treatments for neurological disorders, particularly acute ischemic stroke (AIS) and chronic kidney disease (CKD).
Core Business Areas
- AIS Treatment: Developing DM199, a recombinant form of human tissue kallikrein-1 (KLK1), as a treatment for acute ischemic stroke.
- CKD Treatment: Exploring DM199's potential in treating chronic kidney disease.
Leadership and Structure
Rick Pauls is the Chairman and CEO. The company has a typical biopharmaceutical structure with departments for research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- DM199 (AIS): DM199 is DiaMedica's lead product candidate for the treatment of acute ischemic stroke. Currently in Phase 3 trials (ReMEDy2). The market for stroke treatment is significant, dominated by thrombolytics (like alteplase) and mechanical thrombectomy. Competitors include companies developing neuroprotective agents and improved thrombolytic therapies. Market share data is currently unavailable as the product is not yet approved.
- DM199 (CKD): DM199 is also being explored for the treatment of chronic kidney disease. This is an early-stage program. Competitors include companies developing drugs to slow CKD progression, such as SGLT2 inhibitors and mineralocorticoid receptor antagonists.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with significant regulatory hurdles. There is a high unmet need for improved stroke and CKD treatments.
Positioning
DiaMedica is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological and kidney disorders. Their competitive advantage lies in their proprietary KLK1 technology, DM199.
Total Addressable Market (TAM)
The TAM for stroke treatment is estimated to be in the billions of dollars annually. CKD represents another multi-billion dollar market. DiaMedica aims to capture a portion of these markets with DM199, focusing on patients who may benefit from KLK1 therapy.
Upturn SWOT Analysis
Strengths
- Novel KLK1 technology platform
- Lead product candidate (DM199) in Phase 3 trials
- Experienced management team
- Focus on high unmet medical needs
Weaknesses
- Clinical trial risks and regulatory approval challenges
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on a single product candidate
- No current revenue stream
Opportunities
- Successful completion of Phase 3 trials for DM199 in stroke
- Potential for regulatory approval and commercialization of DM199
- Expansion of DM199 to other indications
- Partnerships with larger pharmaceutical companies
Threats
- Failure to achieve positive clinical trial results
- Regulatory delays or rejection
- Competition from other companies developing stroke and CKD therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- ALNY
- BIIB
- AVXL
Competitive Landscape
DiaMedica faces competition from established pharmaceutical companies and smaller biotech firms developing treatments for stroke and CKD. They aim to differentiate themselves with their unique KLK1-based therapy.
Growth Trajectory and Initiatives
Historical Growth: DiaMedica's growth has been characterized by advancing DM199 through clinical development stages.
Future Projections: Future growth depends heavily on the success of the ReMEDy2 Phase 3 trial for DM199 in stroke. Analyst estimates are not available, but success could lead to significant revenue potential.
Recent Initiatives: Initiatives include the ongoing ReMEDy2 Phase 3 trial and strategic partnerships to support clinical development.
Summary
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company with potential in DM199 for stroke and CKD. Success hinges on Phase 3 trial results, presenting significant risk and opportunity. Limited resources and reliance on a single asset are key challenges. Positive data could lead to partnerships and market entry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- DiaMedica Therapeutics Inc. website
- SEC filings
- Company press releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DiaMedica Therapeutics Inc
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2008-01-04 | President, CEO & Director Mr. Dietrich John Pauls MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 27 | Website https://www.diamedica.com |
Full time employees 27 | Website https://www.diamedica.com | ||
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.